Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

rutlandherald · · 1 min read

Clinically Reviewed by Editorial Advisory Panel
anxiety
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/merck-and-eisai-provide-update-on-phase-3-litespark-012-trial-evaluating-first-line-combination/article_96229ead-e9d2-5749-beb3-16a5a1fe1a0f.html